CD4 and lung cancer: Although OS did not differ by age, sex, smoking, HAART, complication, CD4+ count, or pathological type among these patients by univariate analysis with SPSS, there were significant differences in survival outcome between TMN stages I-II (17.66 ± 2.88 months) and stages III-IV (10.46 ± 1.87 months) (p = 0.026) by pairwise comparison analysis among pathological types of HIV-associated lung cancer.